🔥PrEP 4 SARS-CoV-2🔥 ➡️casirivimab/imdevimab ⚡️Detection @ D1 and stabilisation up to D30 of serum and saliva Abs in IMID pts who failed response 2 COVID vax. ❓role in preventing severe infxn in high risk pts refractory 2 vax #ACR22 @RheumNow Abst 2195 @Dr_David_Simon https://t.co/Zd00P5l363

Abstr # 1878 looked at biomarkers assoc w/ MRI muscle inflammation in #IIM - Of the potential cytokines, IL-7 strongly correlated with muscle damage on MRI thigh bilateral @RheumNow #ACR22 #Myositis https://t.co/3i3C2EGtFM

Smartphone app (FM-ACT) - self guided 8 chapters of structured lessons, mindfulness practices and activities w/ paced exercise and behavior change proved beneficial after 12 weeks. Improvement in all areas: pain, sleep, psychological wellbeing Abs#2235 @RheumNow #ACR22 https://t.co/wNhIw4pdJu

61pts with #FMF on Canakinumab - single center in Turkey 35% no attacks attack frequency decreased in 55% no response in 10% - VAS score and inflammatory markers significantly improved #ACR22 @RheumNow abst#1834

#abst0405 #ACR22 @RheumNow Post hoc of ph2/3 trials TOFA for AS: AEs/SAEs ⬆️ in pts w/BMI < 25 kg/m2 vs other BMI categories. Most frequent AEs (≥ 5% of pts) nasopharyngitis, URI& arthralgia. Δ from BL in LFTs similar, while % change from BL in lipid levels ⬆️ in Tofa vs PBO pts https://t.co/WmXD8uVK58

Males w/ sarcoidosis may be more likely to have cardiac involvement. Patients treated with s/bDMARDs had a high response rate as reflected by clinical and imaging improvement. Abs 1846 @RheumNow #ACR22 https://t.co/ibbf4Dckun https://t.co/ZvGxPNFjwm

In bio-naïve PsA pts on GUS, earlier improvements in self-reported health-related measures were sustained through 2 years. Abs 1850 #ACR22 @RheumNow https://t.co/6yhPesE3LZ https://t.co/nVCSgPgcqW

#ACR22 Abstr#L07 Most impressive Delta difference vs Control in #lupus! In Phase 3 RCT in China, more patients in Telitacicept, BAFF/APRIL-i met SRI-4 (delta 44% if data imputed; 34% without). No major safety. Phase 3 in US is in progress. Would be historic! @RheumNow #ACRBest https://t.co/8wL2tkA8ym

Jonassen et al. AP1189, an oral melanocortin agonist in combination with MTX in early RA. Evidence of efficacy, no safety concerns. Looks promising! @RheumNow #ACR22 Abstr#1985 https://t.co/aK7BPwr5Ku https://t.co/9553KT2Pao

van Ouwerkerk et al. Glucocorticoid bridging in new RA associated higher risk of starting bDMARD (aHR 1.68) but not glucocorticoids (aHR 1) later in disease. Why? Maybe it shows what can be achieved? @RheumNow #ACR22 Abstr#1994 https://t.co/5GsXGMOZAm https://t.co/122CuSAqVw